Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients.

Strome, Scott E; Martin, Elizabeth; Flies, Dallas; Khurana, Dianne; Salomao, Diva; Tamada, Koji; Chapoval, Andrei I; Kasperbauer, Jan L et al. · Otolaryngol Head Neck Surg · 2002

basic_science · Level V

Where this comes from

Abstract

CD62L was evaluated as a determinant of human pre-effector T cells. Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status. CD62L(Low) T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-gamma than did CD62L(High) T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62L(Low) tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-gamma. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10. Our results provide evidence that CD62L(Low) T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin. Characterization of this human CD62L(Low) T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.

Medical subject headings